Barczyk A, Pierzchala W, Sozañska E
Department of Pneumology, Silesian Medical Academy, Katowice, Poland.
Respir Med. 2003 Jun;97(6):726-33. doi: 10.1053/rmed.2003.1507.
Interleukin-17 (IL-17) is a novel cytokine secreted by activated human memory CD4+ T cells. In vivo IL-17 recruits neutrophils into the airways via the release of CXC chemokines (interleukin-8) from bronchial epithelial cells. Since neutrophils are implicated in pathogenesis of chronic obstructive pulmonary disease (COPD) chronic bronchitis (CB) and asthma, we hypothesized that there would be increased concentration of IL-17 in the airways of these patients. To test this hypothesis, we measured levels of IL-17 in induced sputum of COPD patients, chronic bronchitis and asthmatics and compared them with healthy controls.
Levels of IL-17 in induced sputum were measured via ELISA method in 19 COPD, 16 CB, 10 asthma and 11 control subjects. Airway responsiveness to methacholine was performed in people with FEV1 higher than 70% of predicted.
There were no significant differences in IL-17 levels between control group and the other groups. However, levels of IL-17 in sputum of COPD patients were significantly lower than in asthma (P=0.004) and in CB (P=0.01) groups. Medians and (ranges) were as follows: asthma--37.6 pg/ml (18.8-55.7 pg/ml), CB 293 pg/ml (18.8-49.7 pg/ml) and COPD 24.6 pg/ml (0-34.1 pg/ml). Comparison of healthy control subjects (PC20 > 8 mg/ml) to a group with bronchial hyperreactivity, which consisted of asthmatics and CB patients, whose PC20 was less than 8 mg/ml, revealed that levels of IL-17 were significantly increased in the second group (P=0.02). Also, levels of IL-17 were significantly increased (P=0.02) in the asthmatic patients with bronchial hyperreactivity compared to healthy subjects. Moreover levels of IL-17 in sputum of all studied subjects correlated negatively with PC20 (r=-0.51, P=0.002).
According to our results IL-17 is probably not involved in pathogenesis of stable COPD, but it may play a role in people with airway hyperresponsiveness.
白细胞介素 - 17（IL - 17）是一种由活化的人类记忆性CD4 + T细胞分泌的新型细胞因子。在体内，IL - 17通过促使支气管上皮细胞释放CXC趋化因子（白细胞介素 - 8），将中性粒细胞募集到气道中。由于中性粒细胞与慢性阻塞性肺疾病（COPD）、慢性支气管炎（CB）和哮喘的发病机制有关，我们推测这些患者气道中IL - 17的浓度会升高。为了验证这一假设，我们检测了COPD患者、慢性支气管炎患者和哮喘患者诱导痰中IL - 17的水平，并与健康对照者进行比较。
采用酶联免疫吸附测定（ELISA）法检测19例COPD患者、未提及具体分组数量的16例CB患者、10例哮喘患者和11例对照者诱导痰中IL - 17的水平。对第一秒用力呼气容积（FEV1）高于预测值70%的人群进行了对乙酰甲胆碱的气道反应性检测。
对照组与其他组之间IL - 17水平无显著差异。然而，COPD患者痰中IL - 17水平显著低于哮喘组（P = 0.004）和CB组（P = 0.01）。中位数及（范围）如下：哮喘组——37.6 pg/ml（18.8 - 55.7 pg/ml），CB组293 pg/ml（18.8 - 49.7 pg/ml），COPD组24.6 pg/ml（0 - 34.1 pg/ml）。将健康对照者（PC20 > 8 mg/ml）与支气管高反应性组（由PC20小于8 mg/ml的哮喘患者和CB患者组成）进行比较，结果显示第二组中IL - 17水平显著升高（P = 0.02）。此外，与健康受试者相比，支气管高反应性哮喘患者的IL - 17水平也显著升高（P = 0.02）。而且，所有研究对象痰中IL - 17水平与PC20呈负相关（r = -0.51，P = 0.002）。
根据我们的研究结果，IL - 17可能不参与稳定期COPD的发病机制，但可能在气道高反应性患者中发挥作用。
